Million-dollar ad campaign characters such as the Marlboro Man and Joe Camel lured many people to take up the tobacco habit through magazine ads and TV commercials. Gimmicks such as […] Read more
Nivolumab significantly improved investigator-reported progression-free survival and overall survival compared with placebo in patients with relapsed malignant mesothelioma, according to preliminary results of the CONFIRM phase III trial presented during […] Read more
The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase […] Read more
KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC
Kara Nyberg, PhDPatients with metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50% face greater toxicity without the benefit of enhanced efficacy when ipilimumab is combined with pembrolizumab in the […] Read more
LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC
Kara Nyberg, PhDPrimary results of the phase II Lung Cancer Mutation Consortium (LCMC) 3 clinical trial suggest that neoadjuvant atezolizumab may be a worthwhile treatment option for selected patients with resectable stage […] Read more
Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC
Evaluation of mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes in patients with resected stage II-III NSCLC, according to results of the ITACA study, […] Read more
Lung Cancer Screening Study in East Asia Successful at Identifying Early-Stage Disease
TALENT, a national lung cancer screening study conducted in Taiwan in 12,011 individuals, uncovered the presence of lung cancer in 2.6% of the study population (Abstract PS01.02). These results are […] Read more
Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials
Approximately 10% of “real-world” patients with malignant pleural mesothelioma (MPM) benefitted from checkpoint inhibitor therapy with nivolumab, according to the results of a trial presented by Robert A. Belderbos, MD, […] Read more
Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma
Kara Nyberg, PhDThe largest real-world cohort study of individuals with malignant pleural mesothelioma (MPM) found a median survival duration of 8 months regardless of whether patients received first-line treatment with cisplatin-based chemotherapy […] Read more
A Holistic Approach to Patient Care
Lauren Evoy DavisTreating the whole patient, not just the disease, is a basic tenet of holistic care. Understanding the physical, emotional, and spiritual needs of patients can help providers provide optimal care […] Read more